The text has been copied to the clipboard
EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.
Journal article

EORTC-1203-GITCG - the "INNOVATION"-trial: Effect of chemotherapy alone versus chemotherapy plus trastuzumab, versus chemotherapy plus trastuzumab plus pertuzumab, in the perioperative treatment of HER2 positive, gastric and gastroesophageal junction adenocarcinoma on pathologic response rate: a randomized phase II-intergroup trial of the EORTC-Gastrointestinal Tract Cancer Group, Korean Cancer Study Group and Dutch Upper GI-Cancer group.

  • Wagner AD Department of Oncology, Lausanne University Hospital and University of Lausanne, Bugnon 46, 1011, Lausanne, Switzerland. dorothea.wagner@chuv.ch.
  • Grabsch HI Department of Pathology and GROW School for Oncology and Developmental Biology, Maastricht University Medical Center+, Maastricht, Netherlands.
  • Mauer M EORTC Headquarters, Avenue E. Mounier 83, 1200, Bruxelles, Belgium.
  • Marreaud S EORTC Headquarters, Avenue E. Mounier 83, 1200, Bruxelles, Belgium.
  • Caballero C EORTC Headquarters, Avenue E. Mounier 83, 1200, Bruxelles, Belgium.
  • Thuss-Patience P Department of Hematology, Medical Oncology and Tumor Immunology, Augustenburger Platz 1, Charité Universitätsmedizin Berlin, 13353, Berlin, Germany.
  • Mueller L OnkologieUnterEms, 26789, Leer, Germany.
  • Elme A North Estonian Regional Hospital Cancer Center, Hiiu 44, 11619, Tallinn, Estonia.
  • Moehler MH University Medical Center, Johannes Gutenberg University Mainz, Langenbeckstr. 1, 55131, Mainz, Germany.
  • Martens U Department of Internal Medicine III, SLK-Kliniken Heilbronn GmbH, Am Gesundbrunnen 20-26, 74078, Heilbronn, Germany.
  • Kang YK Department of Oncology, University of Ulsan College of Medicine, Asan Medical Center, Seoul, Republic of Korea.
  • Rha SY Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Korea.
  • Cats A Department of Gastrointestinal Oncology, Netherlands Cancer Institute, Plesmalaaan 121, 1066, Amsterdam, CX, Netherlands.
  • Tokunaga M Division of Gastric Surgery, National Cancer Center Hospital East, 6-5-1, Kashiwanoha, Kashiwa, 277-8577, Japan.
  • Lordick F University Cancer Center, University Medicine Leipzig, Liebigstr. 20, 04103, Leipzig, Germany.
Show more…
  • 2019-05-26
Published in:
  • BMC cancer. - 2019
English BACKGROUND
10-20% of patients with gastric cancer (GC) have HER2+ tumors. Addition of trastuzumab (T) to cisplatin/fluoropyrimidine-based chemotherapy (CT) improved survival in metastatic, HER2+ GC. When pertuzumab (P) was added to neoadjuvant T and CT, a significant increase in histopathological complete response rate was observed in HER2+ breast cancer. This study aims to investigate the added benefit of using both HER2 targeting drugs (T alone or the combination of T + P), in combination with perioperative CT for localized HER2+ GC.


METHODS
This is a prospective, randomized, open-label, phase II trial. HER2 status from patients with resectable GC (UICC TNM7 tumor stage Ib-III) will be centrally determined. Two hundred and-fifteen patients from 52 sites in 14 countries will be centrally randomized (1:2:2 ratio) to one of the following treatment arms: 1. Standard: CT alone. CT regimens will be FLOT (5-FU, leucovorin, oxaliplatin, taxotere) CapOx (capecitabine, oxaliplatin) or FOLFOX (5-FU, leucovorin, oxaliplatin) according to investigator's choice in Europe, and cisplatin/capecitabine in Asia. 2. Experimental arm 1: CT as in control group, plus T (8 mg/kg loading dose, followed by 6 mg/kg every 3 weeks) at day 1, independent of CT chosen for 3 cycles of 3 weeks before and after surgery. 3. Experimental arm 2: CT plus T as in experimental arm 1, plus P (840 mg every 3 weeks) on day 1. Adjuvant treatment with T or T + P will continue for 17 cycles in total. Stratification factors are: histology (intestinal/non-intestinal); region (Asia vs Europe); location (GEJ vs non-GEJ); HER2 immunohistochemistry score (IHC 3+ vs IHC 2+/FISH+) and chemotherapy regimen. Primary objective is to detect an increase in the major pathological response rate from 25 to 45% either with CT plus T alone, or with CT plus the combination of T and P.


DISCUSSION
Depending on the results of the INNOVATION trial, the addition of HER2 targeted treatment with either T or T and P to CT may inform future study designs or become a standard in the perioperative management HER2+ GC.


TRIAL REGISTRATION
This article reports a health care intervention on human participants and was registered on July 10, 2014 under ClinicalTrials.gov identifier: NCT02205047 ; EudraCT: 2014-000722-38.
Language
  • English
Open access status
gold
Identifiers
Persistent URL
https://sonar.ch/global/documents/259586
Export to…

Statistics

Document views: 76 File downloads: